Full-Life Technologies

Full-Life Technologies is a global radiotherapeutics company founded in 2021 and headquartered in Shanghai, China, with operations in Belgium, Germany, and the United States.

The company focuses on the entire value chain of radiopharmaceuticals, including research, development, production, and commercialization, aiming to improve cancer treatment outcomes through innovative therapies. The company specializes in targeted cancer therapy services, offering precision nuclear medicine development, radionuclide-drug conjugates, and clinical-stage asset management. Its product pipeline features targeted solutions that utilize radionuclides for precise tumor delivery, including proprietary offerings like UniRDCTM and advancements in radiopharmaceuticals. Full-Life Technologies primarily serves clients in the healthcare and life sciences sectors, including healthcare providers, pharmaceutical companies, and research institutions. The company has successfully raised significant funding to support its mission of enhancing cancer treatment through advanced radiopharmaceutical research.